Tags

Type your tag names separated by a space and hit enter

Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Pancreas 2015; 44(2):311-20P

Abstract

OBJECTIVE

The aims of this study were to investigate the GNAS mutational status in pancreatic intraductal papillary mucinous neoplasm (IPMN) with and without distinct pancreatic ductal adenocarcinoma (PDAC) and to evaluate the significance of GNAS analysis using duodenal fluid (DF) in patients with IPMN.

METHODS

The clinicopathologic features of 110 patients with IPMN including 16 with distinct PDAC were reviewed. The GNAS status in the IPMN tissue and 23 DF specimens was assessed by sensitive mutation scanning methods.

RESULTS

The GNAS mutation rate in IPMN with distinct PDAC was significantly lower than that in IPMN without PDAC (4/16, 25%, vs 61/94, 65%; P = 0.0047). By multivariate analysis, GNAS wild-type and gastric type IPMNs were significantly associated with distinct PDAC. Of 45 GNAS wild-type IPMNs, 10 (43%) of 23 gastric type IPMNs had distinct PDAC, whereas only 2 (9%) of 22 non-gastric type IPMNs had distinct PDAC (P = 0.017). The GNAS status in DF was consistent with that in tissue in 21 (91%) of 23 patients.

CONCLUSIONS

Distinct PDACs frequently develop in the pancreas with gastric type IPMN without GNAS mutations. Duodenal fluid DNA test would predict the GNAS status of IPMN, whereas the detection of the gastric subtype using noninvasive test remains to be determined.

Authors+Show Affiliations

From the *Departments of Surgery and Oncology, and †Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Studies
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25479586

Citation

Ideno, Noboru, et al. "Clinical Significance of GNAS Mutation in Intraductal Papillary Mucinous Neoplasm of the Pancreas With Concomitant Pancreatic Ductal Adenocarcinoma." Pancreas, vol. 44, no. 2, 2015, pp. 311-20.
Ideno N, Ohtsuka T, Matsunaga T, et al. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Pancreas. 2015;44(2):311-20.
Ideno, N., Ohtsuka, T., Matsunaga, T., Kimura, H., Watanabe, Y., Tamura, K., ... Tanaka, M. (2015). Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Pancreas, 44(2), pp. 311-20. doi:10.1097/MPA.0000000000000258.
Ideno N, et al. Clinical Significance of GNAS Mutation in Intraductal Papillary Mucinous Neoplasm of the Pancreas With Concomitant Pancreatic Ductal Adenocarcinoma. Pancreas. 2015;44(2):311-20. PubMed PMID: 25479586.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. AU - Ideno,Noboru, AU - Ohtsuka,Takao, AU - Matsunaga,Taketo, AU - Kimura,Hideyo, AU - Watanabe,Yusuke, AU - Tamura,Koji, AU - Aso,Teppei, AU - Aishima,Shinichi, AU - Miyasaka,Yoshihiro, AU - Ohuchida,Kenoki, AU - Ueda,Junji, AU - Takahata,Shunichi, AU - Oda,Yoshinao, AU - Mizumoto,Kazuhiro, AU - Tanaka,Masao, PY - 2014/12/6/entrez PY - 2014/12/6/pubmed PY - 2015/12/15/medline SP - 311 EP - 20 JF - Pancreas JO - Pancreas VL - 44 IS - 2 N2 - OBJECTIVE: The aims of this study were to investigate the GNAS mutational status in pancreatic intraductal papillary mucinous neoplasm (IPMN) with and without distinct pancreatic ductal adenocarcinoma (PDAC) and to evaluate the significance of GNAS analysis using duodenal fluid (DF) in patients with IPMN. METHODS: The clinicopathologic features of 110 patients with IPMN including 16 with distinct PDAC were reviewed. The GNAS status in the IPMN tissue and 23 DF specimens was assessed by sensitive mutation scanning methods. RESULTS: The GNAS mutation rate in IPMN with distinct PDAC was significantly lower than that in IPMN without PDAC (4/16, 25%, vs 61/94, 65%; P = 0.0047). By multivariate analysis, GNAS wild-type and gastric type IPMNs were significantly associated with distinct PDAC. Of 45 GNAS wild-type IPMNs, 10 (43%) of 23 gastric type IPMNs had distinct PDAC, whereas only 2 (9%) of 22 non-gastric type IPMNs had distinct PDAC (P = 0.017). The GNAS status in DF was consistent with that in tissue in 21 (91%) of 23 patients. CONCLUSIONS: Distinct PDACs frequently develop in the pancreas with gastric type IPMN without GNAS mutations. Duodenal fluid DNA test would predict the GNAS status of IPMN, whereas the detection of the gastric subtype using noninvasive test remains to be determined. SN - 1536-4828 UR - https://www.unboundmedicine.com/medline/citation/25479586/Clinical_significance_of_GNAS_mutation_in_intraductal_papillary_mucinous_neoplasm_of_the_pancreas_with_concomitant_pancreatic_ductal_adenocarcinoma_ L2 - http://Insights.ovid.com/pubmed?pmid=25479586 DB - PRIME DP - Unbound Medicine ER -